Story
AbbVie's Rinvoq Secures EU Approval for Pediatric Arthritis
Summary
AbbVie announced it has received approval from the European Commission for its immunology drug Rinvoq to treat active polyarticular juvenile idiopathic arthritis in patients two years and older.
AbbVie Inc. (NYSE: ABBV) announced on Tuesday that it has received approval from the European Commission for its drug Rinvoq to treat a form of pediatric arthritis, further expanding the blockbuster drug's list of approved uses in the European Union.
Details of the Approval
According to a statement from the pharmaceutical company, the approval covers the use of Rinvoq, known generically as upadacitinib, for the treatment of active polyarticular juvenile idiopathic arthritis.
The therapy is now authorized for patients two years of age and older who have not responded adequately to one or more prior disease-modifying anti-rheumatic drugs (DMARDs).
Strategic Importance for AbbVie
AdThis latest regulatory milestone is significant for AbbVie as it broadens the addressable market for Rinvoq, a key asset in the company's immunology portfolio and a critical component of its growth strategy.
Expanding the label for key drugs is crucial for AbbVie as it seeks to build revenue streams beyond its older blockbuster, Humira. Rinvoq is already a major commercial success, with existing EU approvals for several other inflammatory conditions, including:
- Rheumatoid arthritis
- Psoriatic arthritis
- Atopic dermatitis
Read next
More on Stocks
ECB Chief Economist Warns 'Second Wave' of Energy Costs to Keep Inflation Elevated
European Central Bank Chief Economist Philip Lane stated that a new surge in energy prices will likely keep euro zone inflation higher and more persistent, delaying a return to the bank's 2% target.
RBC Downgrades LVMH, Cites Weakening Luxury Demand and Macro Headwinds
RBC Capital Markets lowered its rating on LVMH to 'sector perform' and cut its price target, pointing to a challenging macroeconomic environment and softening consumer spending on luxury goods expected to persist into 2027.
On Holding Announces $1 Billion Share Buyback Program, Sets 2029 Growth Targets
The Swiss sportswear company has authorized a share repurchase program of up to $1 billion through 2029 and unveiled ambitious new long-term financial goals at its investor day.
Taiwan Weighted Index Hits New All-Time High on Tech Sector Strength
Taiwan's benchmark stock index, the Taiwan Weighted, climbed 0.26% to a record close, buoyed by strong performance in the electronics and machinery sectors even as more stocks fell than rose.